Drugs / BGB-43395
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07226349 | Dec 2025 → Nov 2028 expected | neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT06756932 | Feb 2025 → Jul 2027 expected | hormone receptor-positive breast cancer | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT06761898 | Jan → May 2025 | — | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT06253195 | Apr 2024 → Apr 2026 | hormone receptor-positive breast cancer, metastatic neoplasm | BeOne Medicines | Completed | No outcome recorded |
| Phase 1 | NCT06257264 | Mar 2024 → Aug 2026 overdue | endometrial cancer, gastric cancer, gastroesophageal cancer, hormone receptor-positive breast cancer +5 | BeiGene | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06120283 | Dec 2023 → Nov 2028 expected | hormone receptor-positive breast cancer, non-small cell lung carcinoma | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07492641 | May 2026 → Apr 2029 expected | hormone receptor-positive breast cancer | BeOne Medicines | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-43395 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06253195 ↗ |
| Action | Inhibit | “a selective cyclin-dependent kinase 4 (CDK4) inhibitor” NCT06120283 ↗ |
| Route | Oral | “Planned doses administered orally.” NCT06120283 ↗ |
| Target | CDK4 | “a selective cyclin-dependent kinase 4 (CDK4) inhibitor” NCT06120283 ↗ |